What We Know About Risks of Stopping Ozempic or Zepbound

Patients who stop taking GLP-1 drugs such as Ozempic and Zepbound face a cluster of rebound effects, according to a physician cited in a report published by Fox News. The drugs, originally developed to manage diabetes, have become widely used for weight loss, and the report centers on what happens to the body once dosing ends.

The physician identifies six risks tied to discontinuation. Among those named in the reporting are weight regain, loss of lean muscle mass, worsening of certain health biomarkers, and mental health consequences. Fox News did not publish the full list of all six risks in the material reviewed for this report, and this article does not speculate on the remaining categories beyond what the physician described.

What happens to weight after stopping the drugs?

Weight regain is the risk most commonly associated with GLP-1 discontinuation, according to the report. The drugs work by suppressing appetite and slowing digestion; once that mechanism is removed, patients often see appetite return toward pre-treatment levels, which the physician links to regained weight.

Why does muscle loss follow GLP-1 discontinuation?

Muscle loss is listed as a separate but related concern. Patients on GLP-1 therapy can lose lean muscle mass alongside fat during treatment, and the physician's warning suggests that risk does not necessarily reverse simply because the drug is stopped. Fox News' health coverage has separately reported on habits aimed at preserving muscle during GLP-1 use, including a piece describing a six-minute daily habit that an expert said could help users retain muscle mass.

What biomarkers tend to worsen after stopping?

The report also flags worsening biomarkers as a consequence of discontinuation, though the specific lab values or thresholds were not detailed in the material available. Patients considering stopping treatment are advised by the physician to discuss monitoring with their own care team rather than relying on general guidance.

Are there mental health risks tied to stopping treatment?

Mental health consequences round out the named risks in the Fox News report. GLP-1 drugs have drawn attention for effects beyond metabolism, and the physician's inclusion of mental health in the list of discontinuation risks points to a broader conversation among clinicians about what patients should expect once they come off the medication.

What should patients ask before stopping a GLP-1 drug?

The underlying message from the physician, as reported, is that stopping Ozempic or Zepbound is not a neutral event. Patients weighing discontinuation are encouraged to raise the specific risks — regain, muscle loss, biomarker shifts, and mental health — directly with a prescribing doctor before making changes, since individual response to stopping treatment can vary.

Fox News' report is the originating account of this physician's warning, and readers seeking the complete breakdown of all six risks should consult the full Fox News article directly.